Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis
Autor
Fernández-Bravo-Rodrigo, Jaime
Cavero-Redondo, Iván
Lucerón-Lucas-Torres, Maribel
Martínez-García, Irene
Flor-García, Amparo
Barreda-Hernández, Dolores
Pascual-Morena, Carlos
Resumen
Background: Migraine is a common and disabling primary headache disorder. Several drugs targeting calcitonin gene-related peptide (CGRP), such as erenumab (an anti-CGRP receptor mAb), have been developed recently. However, the real-world effects of erenumab are not well understood. Objective: To assess the clinical effectiveness and safety of erenumab for reducing migraine intensity and frequency in the real world. Methods: A systematic search of PubMed, Scopus, Web of Science and the Cochrane Library was conducted from inception to December 2023. Studies estimating the real-world effect of erenumab on monthly migraine days (MMD), monthly headache days (MHD), headache impact test (HIT-6), number of days in medication (NDM), acute monthly intake (AMI), pain intensity (PI) and safety outcomes were included. Meta-analyses of proportions or mean differences were performed. Results: Fifty-three studies were included. At 3-months, the effect was −7.18 days for MMD, −6.89 days for MHD, −6.97 for HIT-6, -6.22 days for NDM, −15.75 for AMI, and −1.71 for PI. Generally, the effect at 6- and 12-months increased slightly and gradually. The MMD/MHD response rates revealed that approximately one-third of patients exhibited a response greater than 30%, while one-sixth demonstrated a response exceeding 50%. Additionally, 3–4% of patients achieved a response rate of 100%. Adverse event rates were 0.34 and 0.43 at 6- and 12-months, respectively. Conclusion: This study provides strong evidence of the effectiveness and safety of erenumab in the real world; to our knowledge, this is the first real-world meta-analysis specific to erenumab. Erenumab represents a solid therapeutic option for physicians. © 2024 Elsevier B.V.
Colecciones
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Article
Exercise versus metformin to improve pregnancy outcomes among overweight pregnant women: A systematic review and network meta-analysis (2021)
Pascual-Morena, Carlos; Cavero-Redondo, Iván; Álvarez-Bueno, Celia; Lucerón-Lucas-Torres, Maribel Isabel; Sanabria-Martínez, Gema; Poyatos-Leõn, Raquel; Rodríguez-Martín, Beatriz; Martinez Vizcaino, Vicente J. (MDPI AG, 2021-08-02)Being overweight is associated with pregnancy-related disorders such as gestational diabetes mellitus (GDM), hypertensive disorders of pregnancy (HDP), and excessive maternal weight gain (MWG). Exercise and metformin reduce ... -
Article
Genetic modifiers and phenotype of Duchenne muscular dystrophy: A systematic review and meta-analysis (2021)
Pascual-Morena, Carlos; Cavero-Redondo, Iván; Saz-Lara, Alicia; Sequí-Domínguez, Irene; Lucerón-Lucas-Torres, Maribel Isabel; Martinez Vizcaino, Vicente J. (MDPI AG, 2021-08)The transforming growth factor beta (TGFβ) pathway could modulate the Duchenne muscular dystrophy (DMD) phenotype. This meta-analysis aims to estimate the association of genetic variants involved in the TGFβ pathway, ... -
Article
Association between arterial stiffness and orthostatic hypotension: A systematic review and meta-analysis (2024)
Saz-Lara, Alicia; Cavero-Redondo, Iván; Martínez-Vizcaíno, Vicente; Lucerón-Lucas-Torres, Maribel; Pascual-Morena, Carlos; Sequí-Domínguez, Irese (Frontiers Media S.A., 2023)Background: Orthostatic hypotension, defined as a decrease in blood pressure on standing, is associated with an increased risk of mortality and cardiovascular events in the general population. In addition, it has recently ...